Research and Markets: Neurodegenerative Market Forecast to 2013

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/3e49fa/neurodegenerative) has
announced the addition of Cutting Edge Information's new report
"Neurodegenerative Market Forecast to 2013" to their offering.

Comprehensive Forecasts for Neurodegenerative Conditions. The neurodegenerative
space is a top-selling pharmaceutical market. Consider these facts:

* Sales among all drugs profiled in this report total $18.5 billion and are
expected to increase 62% to $29.7 billion by 2012.
* The majority of this growth is projected to be in multiple sclerosis, which
will increase from a $12.6 billion market to upwards of $20 billion in 2012.

Neurodegenerative disease patients have few treatment options, which often
provide only limited effectiveness. Companies that can invest in and develop
new, tolerable therapies which improve patients' quality of life could see
hundreds of millions - or even billions - of dollars in sales.

In one convenient, easy-to-access format, Neurodegenerative Market Forecast to
2013 provides a compelling, full picture of the Alzheimer's, Multiple Sclerosis
and Parkinson's markets.

CEI's veteran analysts examine 40 brands representing different classes and
stages of development. The profiled products represent over 90% of sales in the
neurodegenerative market. Each drug profile has the following components:

* Drug history
* Competitive and strategic positioning:
* Market growth opportunities
* Charts containing market exclusivity and patent information for approved drugs

* Clinical trial data tables to quickly show clinical detail:

Companies Mentioned:

* Eli Lilly
* Pfizer
* Wyeth
* Bristol-Myers Squibb
* Biogen Idec
* Genentech
* GlaxoSmithKline
* Novartis
* AstraZeneca

Profiled Brands:

* ALZHEIMER'S DISEASE
* MULTIPLE SCLEROSIS (MS)
* PARKINSON'S

Analyses weigh the challenges and opportunities of each indication, class, and
individual brand. Which brands will reap dividends and why? Whose sales are
expected to drop? Which experimental therapies represent the next great medical
breakthrough? Who will be the markets' leaders in the next decade? Give your
brand team all the data it needs to make critical product decisions!

For more information visit
http://www.researchandmarkets.com/research/3e49fa/neurodegenerative

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009